Last reviewed · How we verify
Dukoral®
At a glance
| Generic name | Dukoral® |
|---|---|
| Sponsor | International Vaccine Institute |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Trial to Evaluate Immunogenicity Non-Inferiority, Safety and Lot-to-Lot Consistency of Biovac OCV-S to Euvichol®-Plus (PHASE3)
- Safety and Immunogenicity Study of the DuoChol Oral Cholera Vaccine in Healthy Participants (PHASE1)
- Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines (PHASE4)
- Immune Response to a Delayed Second Dose of Oral Cholera Vaccine (PHASE4)
- To Evaluate Safety of Oral Cholera Vaccine Hillchol® (BBV131) (PHASE3)
- A Phase III Randomized, Modified Double-blind, Multi-centric, Comparative Study, to Evaluate the Non-inferiority of Immunogenicity and Safety of Hillchol® (BBV131)to Shanchol™ Along With Lot-to-lot Consistency of Hillchol®(BBV131). (PHASE3)
- Vaccine Hyporesponse in Healthy Elderly Participants (MK-0000-131 AM2)
- Safety and Immunogenicity of a New Formulation of Euvichol® (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dukoral® CI brief — competitive landscape report
- Dukoral® updates RSS · CI watch RSS
- International Vaccine Institute portfolio CI